Antibody-targeted RNase Fusion Proteins (immunoRNases) for Cancer Therapy
Overview
Pharmacology
Affiliations
Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anti-cancer therapeutics.
Jafary B, Akbarzadeh-Khiavi M, Farzi-Khajeh H, Safary A, Adibkia K Sci Rep. 2025; 15(1):1483.
PMID: 39789190 PMC: 11718297. DOI: 10.1038/s41598-025-85856-9.
Pourali P, Dzmitruk V, Patek M, Neuhoferova E, Svoboda M, Benson V Sci Rep. 2023; 13(1):4916.
PMID: 36966192 PMC: 10039949. DOI: 10.1038/s41598-023-31792-5.
Antibody-Based Immunotoxins for Colorectal Cancer Therapy.
Sanz L, Ibanez-Perez R, Guerrero-Ochoa P, Lacadena J, Anel A Biomedicines. 2021; 9(11).
PMID: 34829955 PMC: 8615520. DOI: 10.3390/biomedicines9111729.
Immune Modulation by Human Secreted RNases at the Extracellular Space.
Lu L, Li J, Moussaoui M, Boix E Front Immunol. 2018; 9:1012.
PMID: 29867984 PMC: 5964141. DOI: 10.3389/fimmu.2018.01012.
Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
Jordaan S, Akinrinmade O, Nachreiner T, Cremer C, Naran K, Chetty S Biomedicines. 2018; 6(1).
PMID: 29510557 PMC: 5874685. DOI: 10.3390/biomedicines6010028.